Loading clinical trials...
Loading clinical trials...
This study is an open-label, 2-Part (Single Ascending Dose \[Part 1\] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB)....
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Epigenic Therapeutics, Inc
NCT06092333 · Chronic Hepatitis B
NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis
NCT02932150 · Chronic Hepatitis B
NCT07343778 · Chronic Hepatitis B With Hepatic Fibrosis
NCT06671093 · Chronic Hep B, Chronic Hepatitis b, and more
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions